-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962

Benzinga·08/03/2026 12:05:09
Listen to the news
Barclays analyst Eliana Merle maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight and lowers the price target from $964 to $962.